[Br:1][C:2]1[CH:7]=[CH:6][C:5]([C@@H:8]([N:10]2[CH2:15][CH2:14][C@:13]([CH2:22][C:23]([CH3:25])=[CH2:24])([C:16]3[CH:21]=[CH:20][CH:19]=[CH:18][CH:17]=3)[NH:12]C2=O)[CH3:9])=[CH:4][CH:3]=1.S([C:37]#[N:38])(C1C=CC(C)=CC=1)(=O)=O.C(OO)(C)(C)C.C1([SiH3])C=CC=CC=1.C[CH2:53][OH:54]>[Co]>[Br:1][C:2]1[CH:3]=[CH:4][C:5]([C@@H:8]([N:10]2[CH2:15][CH2:14][C@:13]([CH2:22][C:23]([CH3:24])([CH3:25])[C:37]#[N:38])([C:16]3[CH:17]=[CH:18][CH:19]=[CH:20][CH:21]=3)[NH:12][C:53]2=[O:54])[CH3:9])=[CH:6][CH:7]=1Cobalt catalyst 1 (1.32 mg, 0.002 mmol, 1 mol %) was dissolved in EtOH (8 mL; absolute) at rt under argon, (R)-1-((S)-1-(4-bromophenyl)ethyl)-4-(2-methylallyl)-4-phenyltetrahydropyrimidin-2(1H)-one (82.6 mg, 0.2 mmol), TsCN (54 mg, 0.3 mmol), tBuOOH (6 mg, 0.06 mmol), and PhSiH3 (21.6 mg, 0.2 mmol) were added. The resulting solution was stirred at rt for 3 h. The solvent was removed by evaporation, and the residue was purified by prep HPLC to afford 3-((R)-1-((S)-1-(4-bromophenyl)ethyl)-2-oxo-4-phenylhexahydropyrimidin-4-yl)-2,2-dimethylpropanenitrile (4 mg, 4.5%) as a white solid. 1H NMR (CD3OD): δ 1.24 (s, 3H), 1.36 (s, 3H), 1.47-1.48 (m, 3H), 2.04-2.07 (m, 2H), 2.07 (m, 1H), 2.22-2.26 (m, 2H), 2.98-3.02 (m, 1H), 5.65-5.67 (m, 1H), 6.95-6.97 (m, 1H), 7.25-7.30 (m, 3H), 7.33-7.37 (m, 4H).
Loading…